Clinical Trials

Clinical Trial Program 2017/2018

ECWM-1 (https://clinicaltrials.gov/ct2/show/NCT01788020?term=ECWM-1&rank=1)

Study Design: Phase III, randomized, multicenter, international trial

Patients: treatment naive WM patients

Treatment: DRC versus Bortezomib-DRC

Status of the Study: Patient recruitment: closed (last patient in Sept 2018, n = 202)

Sponsor: University Hospital of Ulm, PI Christian Buske

ECWM-2 (https://clinicaltrials.gov/ct2/show/NCT03620903?term=ECWM-2&rank=1)

Study Design: Phase II, single arm, multicenter, international

Patients: treatment naive WM patients

Treatment: Bortezomib-Rituximab-Ibrutinib

Status of the Study: not yet recruiting (first patient in planned Q1 2019, n= 53)

Sponsor: University Hospital of Ulm, PI Christian Buske

ECWM-3 (CZAR-1)

Study Design: Phase III, randomized, multicenter, international trial

Patients: treatment naive and relapsed WM patients

Treatment: Carfilzomib/Ibrutinib versus Ibrutinib

Status of the Study: not yet recruiting (first patient in planned Q2 2019, n= 53)

Sponsor: University Hospital of Ulm, PI Christian Buske

HOVON124/ECWM-R2 trial

Study Design: Phase II, single arm, multicenter, European trial

Patients: relapsed WM patients

Treatment:  Ixazomib, rituximab and dexamethasone (IRD)

Status of the Study: recruiting

Sponsor: University Hospital Amsterdam, PI Marie Jose Kersten

ECWM-R3 (Remodel)

Study Design: Phase II, single arm, multicenter, French trial for treatment naive WM patients

Patients: relapsed WM patients

Treatment: Idelalisib-Obinutuzumab

Status of the Study: fully recruited

Sponsor: Tour, France